- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06524544
Een onderzoek waarin de combinatie van pembrolizumab en sacituzumab govitecan wordt vergeleken met sacituzumab govitecan alleen bij de behandeling van gevorderde urotheelkanker
Een gerandomiseerde fase III-studie met pembrolizumab in combinatie met Sacituzumab Govitecan versus alleen Sacituzumab Govitecan bij anti-PD(L)1-resistente gevorderde urotheelkanker
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Geneesmiddel: Carboplatin
- Geneesmiddel: Paclitaxel
- Geneesmiddel: Cisplatin
- Geneesmiddel: Docetaxel
- Procedure: Biospecimen Collection
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Ander: Questionnaire Administration
- Biologisch: Pembrolizumab
- Geneesmiddel: Gemcitabine
- Biologisch: Sacituzumab Govitecan
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
SECONDARY OBJECTIVES:
I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:
I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.
II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.
III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.
ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.
After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85004
- Werving
- Cancer Center at Saint Joseph's
-
Hoofdonderzoeker:
- Loretta J. Nastoupil
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
California
-
Irvine, California, Verenigde Staten, 92612
- Werving
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Hoofdonderzoeker:
- Nataliya Mar
-
Orange, California, Verenigde Staten, 92868
- Werving
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Hoofdonderzoeker:
- Nataliya Mar
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Werving
- UF Health Cancer Institute - Gainesville
-
Hoofdonderzoeker:
- Daniel V. Araujo
-
Contact:
- Site Public Contact
- Telefoonnummer: 352-273-8010
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 404-778-1868
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory University Hospital Midtown
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-946-7447
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Verenigde Staten, 30342
- Werving
- Emory Saint Joseph's Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 404-851-7115
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
-
Idaho
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Werving
- Kootenai Health - Coeur d'Alene
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Post Falls, Idaho, Verenigde Staten, 83854
- Werving
- Kootenai Clinic Cancer Services - Post Falls
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Werving
- Kootenai Clinic Cancer Services - Sandpoint
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Werving
- University of Illinois
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-355-3046
-
Hoofdonderzoeker:
- Karine Tawagi
-
Danville, Illinois, Verenigde Staten, 61832
- Werving
- Carle at The Riverfront
-
Hoofdonderzoeker:
- Priyank P. Patel
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Cancer Care Specialists of Illinois - Decatur
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Decatur Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Priyank P. Patel
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Crossroads Cancer Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Mattoon, Illinois, Verenigde Staten, 61938
- Werving
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Priyank P. Patel
-
Normal, Illinois, Verenigde Staten, 61761
- Werving
- Carle BroMenn Medical Center
-
Hoofdonderzoeker:
- Priyank P. Patel
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Normal, Illinois, Verenigde Staten, 61761
- Werving
- Carle Cancer Institute Normal
-
Hoofdonderzoeker:
- Priyank P. Patel
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- Cancer Care Center of O'Fallon
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- HSHS Saint Elizabeth's Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Shiloh, Illinois, Verenigde Staten, 62269
- Werving
- Memorial Hospital East
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-747-9912
- E-mail: dschwab@wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Southern Illinois University School of Medicine
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-545-7929
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Springfield Clinic
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-444-7541
-
Springfield, Illinois, Verenigde Staten, 62781
- Werving
- Springfield Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Priyank P. Patel
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Werving
- Mary Greeley Medical Center
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
Ames, Iowa, Verenigde Staten, 50010
- Werving
- McFarland Clinic - Ames
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-239-4734
- E-mail: ksoder@mcfarlandclinic.com
-
Boone, Iowa, Verenigde Staten, 50036
- Geschorst
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Werving
- Mercy Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 319-365-4673
-
Hoofdonderzoeker:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Werving
- Oncology Associates at Mercy Medical Center
-
Hoofdonderzoeker:
- Deborah W. Wilbur
-
Contact:
- Site Public Contact
- Telefoonnummer: 319-363-2690
-
Fort Dodge, Iowa, Verenigde Staten, 50501
- Werving
- McFarland Clinic - Trinity Cancer Center
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
Jefferson, Iowa, Verenigde Staten, 50129
- Geschorst
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Verenigde Staten, 50158
- Werving
- McFarland Clinic - Marshalltown
-
Hoofdonderzoeker:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-956-4132
-
-
Kansas
-
Hays, Kansas, Verenigde Staten, 67601
- Werving
- HaysMed
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 785-623-5774
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- University of Kansas Cancer Center
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Verenigde Staten, 66044
- Werving
- Lawrence Memorial Hospital
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 785-505-2800
- E-mail: Stephanie.Norris@LMH.ORG
-
Olathe, Kansas, Verenigde Staten, 66061
- Werving
- The University of Kansas Cancer Center - Olathe
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-1569
- E-mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Verenigde Staten, 66210
- Werving
- University of Kansas Cancer Center-Overland Park
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Salina, Kansas, Verenigde Staten, 67401
- Werving
- Salina Regional Health Center
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 785-452-7038
- E-mail: mleepers@srhc.com
-
Topeka, Kansas, Verenigde Staten, 66606
- Werving
- University of Kansas Health System Saint Francis Campus
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 785-295-8000
-
Westwood, Kansas, Verenigde Staten, 66205
- Werving
- University of Kansas Hospital-Westwood Cancer Center
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- The James Graham Brown Cancer Center at University of Louisville
-
Hoofdonderzoeker:
- Rohit Kumar
-
Contact:
- Site Public Contact
- Telefoonnummer: 502-562-3429
-
Louisville, Kentucky, Verenigde Staten, 40245
- Werving
- UofL Health Medical Center Northeast
-
Hoofdonderzoeker:
- Rohit Kumar
-
Contact:
- Site Public Contact
- Telefoonnummer: 502-852-2755
- E-mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Werving
- Louisiana Hematology Oncology Associates LLC
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-215-1353
- E-mail: clinicalresearch@marybird.com
-
Hoofdonderzoeker:
- Scott E. Delacroix
-
Metairie, Louisiana, Verenigde Staten, 70002
- Werving
- Mary Bird Perkins Cancer Center - Metairie
-
Hoofdonderzoeker:
- Scott E. Delacroix
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-584-6990
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01655
- Werving
- UMass Memorial Medical Center - University Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
Hoofdonderzoeker:
- Kriti Mittal
-
-
Michigan
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Lansing, Michigan, Verenigde Staten, 48912
- Werving
- University of Michigan Health - Sparrow Lansing
-
Contact:
- Site Public Contact
- Telefoonnummer: 517-364-3712
- E-mail: harsha.trivedi@umhsparrow.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Livonia, Michigan, Verenigde Staten, 48154
- Werving
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Werving
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Houssam Y. Hariri
-
-
Minnesota
-
Brainerd, Minnesota, Verenigde Staten, 56401
- Werving
- Essentia Health Saint Joseph's Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Werving
- Mercy Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Deer River, Minnesota, Verenigde Staten, 56636
- Werving
- Essentia Health - Deer River Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Duluth, Minnesota, Verenigde Staten, 55805
- Werving
- Essentia Health Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Fairview Southdale Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Minnesota Oncology - Edina
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Hibbing, Minnesota, Verenigde Staten, 55746
- Werving
- Essentia Health Hibbing Clinic
-
Hoofdonderzoeker:
- Bret E. Friday
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
-
Marshall, Minnesota, Verenigde Staten, 56258
- Werving
- Avera Cancer Institute at Marshall
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Abbott-Northwestern Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Werving
- Park Nicollet Clinic - Saint Louis Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Werving
- Regions Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- Werving
- United Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Sandstone, Minnesota, Verenigde Staten, 55072
- Werving
- Essentia Health Sandstone
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Virginia, Minnesota, Verenigde Staten, 55792
- Werving
- Essentia Health Virginia Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Werving
- Saint Francis Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 573-334-2230
- E-mail: sfmc@sfmc.net
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Werving
- Siteman Cancer Center at Saint Peters Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Werving
- Siteman Cancer Center at West County Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
Farmington, Missouri, Verenigde Staten, 63640
- Werving
- Parkland Health Center - Farmington
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Kansas City, Missouri, Verenigde Staten, 64154
- Werving
- University of Kansas Cancer Center - North
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Verenigde Staten, 64108
- Werving
- University Health Truman Medical Center
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 816-404-4375
-
Kansas City, Missouri, Verenigde Staten, 64116
- Werving
- University of Kansas Cancer Center - Briarcliff
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
-
Lee's Summit, Missouri, Verenigde Staten, 64064
- Werving
- University of Kansas Cancer Center - Lee's Summit
-
Hoofdonderzoeker:
- Saqib Abbasi
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Sainte Genevieve, Missouri, Verenigde Staten, 63670
- Werving
- Sainte Genevieve County Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
St Louis, Missouri, Verenigde Staten, 63129
- Werving
- Siteman Cancer Center-South County
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
St Louis, Missouri, Verenigde Staten, 63136
- Werving
- Siteman Cancer Center at Christian Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Hoofdonderzoeker:
- Melissa A. Reimers
-
St Louis, Missouri, Verenigde Staten, 63131
- Werving
- Missouri Baptist Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Sullivan, Missouri, Verenigde Staten, 63080
- Werving
- Missouri Baptist Sullivan Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Werving
- Community Hospital of Anaconda
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Verenigde Staten, 59101
- Werving
- Billings Clinic Cancer Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, Verenigde Staten, 59715
- Werving
- Bozeman Health Deaconess Hospital
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Verenigde Staten, 59405
- Werving
- Benefis Sletten Cancer Institute
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Verenigde Staten, 59901
- Werving
- Logan Health Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Verenigde Staten, 59804
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Werving
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Hoofdonderzoeker:
- Jacob B. Reibel
-
-
New Jersey
-
Livingston, New Jersey, Verenigde Staten, 07039
- Werving
- Cooperman Barnabas Medical Center
-
Hoofdonderzoeker:
- Biren Saraiya
-
Contact:
- Site Public Contact
- Telefoonnummer: 973-322-5200
-
Long Branch, New Jersey, Verenigde Staten, 07740
- Werving
- Monmouth Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-923-6564
- E-mail: mary.danish@rwjbh.org
-
Hoofdonderzoeker:
- Biren Saraiya
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Werving
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-235-7356
-
Hoofdonderzoeker:
- Biren Saraiya
-
Newark, New Jersey, Verenigde Staten, 07101
- Werving
- Rutgers New Jersey Medical School
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-235-7356
-
Hoofdonderzoeker:
- Biren Saraiya
-
Somerville, New Jersey, Verenigde Staten, 08876
- Werving
- Robert Wood Johnson University Hospital Somerset
-
Hoofdonderzoeker:
- Biren Saraiya
-
Contact:
- Site Public Contact
- Telefoonnummer: 908-685-2481
- E-mail: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, Verenigde Staten, 08755
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- Biren Saraiya
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Werving
- Roswell Park Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Hoofdonderzoeker:
- Ellis G. Levine
-
Stony Brook, New York, Verenigde Staten, 11794
- Werving
- Stony Brook University Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-862-2215
-
Hoofdonderzoeker:
- Judy Huang
-
Williamsville, New York, Verenigde Staten, 14221
- Werving
- Roswell Park Amherst Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Hoofdonderzoeker:
- Ellis G. Levine
-
-
North Carolina
-
Hendersonville, North Carolina, Verenigde Staten, 28791
- Werving
- Margaret R Pardee Memorial Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 828-696-4716
- E-mail: pardeecancerresearch@unchealth.unc.edu
-
Hoofdonderzoeker:
- John K. Hill
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58103
- Werving
- Essentia Health Cancer Center-South University Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Hoofdonderzoeker:
- Yuanquan Yang
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Hoofdonderzoeker:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Werving
- Geisinger Medical Center
-
Hoofdonderzoeker:
- Sorab Gupta
-
Contact:
- Site Public Contact
- Telefoonnummer: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Dickson City, Pennsylvania, Verenigde Staten, 18519
- Werving
- Geisinger Cancer Center Dickson City
-
Hoofdonderzoeker:
- Sorab Gupta
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-204-6081
- E-mail: cancerresearch@geisinger.edu
-
Erie, Pennsylvania, Verenigde Staten, 16505
- Werving
- UPMC Hillman Cancer Center Erie
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Erie, Pennsylvania, Verenigde Staten, 16544
- Werving
- Saint Vincent Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 814-452-5000
-
Hoofdonderzoeker:
- Alexander Helfand
-
Greensburg, Pennsylvania, Verenigde Staten, 15601
- Werving
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Contact:
- Site Public Contact
- Telefoonnummer: 724-838-1900
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Harrisburg, Pennsylvania, Verenigde Staten, 17109
- Werving
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-724-6765
- E-mail: klitchfield@PINNACLEHEALTH.org
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Verenigde Staten, 17033-0850
- Werving
- Penn State Milton S Hershey Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Hoofdonderzoeker:
- Monika Joshi
-
Indiana, Pennsylvania, Verenigde Staten, 15701
- Werving
- IRMC Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-389-5208
- E-mail: haneydl@upmc.edu
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Jefferson Hills, Pennsylvania, Verenigde Staten, 15025
- Werving
- Jefferson Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-359-3043
- E-mail: ddefazio@wpahs.org
-
Hoofdonderzoeker:
- Alexander Helfand
-
Lewisburg, Pennsylvania, Verenigde Staten, 17837
- Werving
- Geisinger Medical Oncology-Lewisburg
-
Hoofdonderzoeker:
- Sorab Gupta
-
Contact:
- Site Public Contact
- Telefoonnummer: 570-523-9200
- E-mail: cancerresearch@geisinger.edu
-
Mechanicsburg, Pennsylvania, Verenigde Staten, 17050
- Werving
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-389-5208
- E-mail: haneydl@upmc.edu
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Monroeville, Pennsylvania, Verenigde Staten, 15146
- Werving
- Forbes Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-858-7746
-
Hoofdonderzoeker:
- Alexander Helfand
-
Monroeville, Pennsylvania, Verenigde Staten, 15146
- Werving
- UPMC Hillman Cancer Center - Monroeville
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Natrona Heights, Pennsylvania, Verenigde Staten, 15065
- Werving
- Allegheny Valley Hospital
-
Contact:
- Site Public Contact
- E-mail: Dawnmarie.DeFazio@ahn.org
-
Hoofdonderzoeker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Werving
- West Penn Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-578-5000
-
Hoofdonderzoeker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15215
- Werving
- UPMC-Saint Margaret
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-784-4900
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15237
- Werving
- UPMC-Passavant Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-367-6454
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- Allegheny General Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-284-2000
-
Hoofdonderzoeker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- Werving
- UPMC Hillman Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-647-8073
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Seneca, Pennsylvania, Verenigde Staten, 16346
- Werving
- UPMC Cancer Center at UPMC Northwest
-
Contact:
- Site Public Contact
- Telefoonnummer: 814-676-7900
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Uniontown, Pennsylvania, Verenigde Staten, 15401
- Werving
- UPMC Cancer Center-Uniontown
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Washington, Pennsylvania, Verenigde Staten, 15301
- Werving
- UPMC Cancer Center-Washington
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Verenigde Staten, 19611
- Werving
- Reading Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 610-988-9323
-
Hoofdonderzoeker:
- Terrence P. Cescon
-
Wexford, Pennsylvania, Verenigde Staten, 15090
- Werving
- Wexford Health and Wellness Pavilion
-
Contact:
- Site Public Contact
- E-mail: Dawnmarie.DeFazio@ahn.org
-
Hoofdonderzoeker:
- Alexander Helfand
-
Wilkes-Barre, Pennsylvania, Verenigde Staten, 18711
- Werving
- Geisinger Wyoming Valley/Henry Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 570-271-5251
- E-mail: HemonCCTrials@geisinger.edu
-
Hoofdonderzoeker:
- Sorab Gupta
-
-
South Dakota
-
Aberdeen, South Dakota, Verenigde Staten, 57401
- Werving
- Avera Cancer Institute-Aberdeen
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-622-8700
- E-mail: oncregulatory@avera.org
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Mitchell, South Dakota, Verenigde Staten, 57301
- Werving
- Avera Cancer Institute - Mitchell
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-322-3096
- E-mail: OncRegulatory@avera.org
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Pierre, South Dakota, Verenigde Staten, 57501
- Werving
- Avera Cancer Institute at Pierre
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Werving
- Avera Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Yankton, South Dakota, Verenigde Staten, 57078
- Werving
- Avera Cancer Institute at Yankton
-
Hoofdonderzoeker:
- Ryan A. Vaca
-
Contact:
- Site Public Contact
- Telefoonnummer: 605-655-1800
- E-mail: OncRegulatory@avera.org
-
-
Texas
-
Baytown, Texas, Verenigde Staten, 77521
- Werving
- Houston Methodist San Jacinto Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Cypress, Texas, Verenigde Staten, 77429
- Werving
- Houston Methodist Cypress Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 346-356-1413
- E-mail: irb@houstonmethodist.org
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Suzanne M. Cole
-
Dallas, Texas, Verenigde Staten, 75235
- Werving
- Parkland Memorial Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Suzanne M. Cole
-
Dallas, Texas, Verenigde Staten, 75237
- Werving
- UT Southwestern Simmons Cancer Center - RedBird
-
Hoofdonderzoeker:
- Suzanne M. Cole
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Suzanne M. Cole
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 713-790-2700
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Houston, Texas, Verenigde Staten, 77070
- Werving
- Methodist Willowbrook Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Houston, Texas, Verenigde Staten, 77094
- Werving
- Houston Methodist West Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 832-522-2873
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Nassau Bay, Texas, Verenigde Staten, 77058
- Werving
- Houston Methodist Saint John Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Hoofdonderzoeker:
- Patrick E. Prath
-
Richardson, Texas, Verenigde Staten, 75080
- Werving
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Telefoonnummer: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Hoofdonderzoeker:
- Suzanne M. Cole
-
Sugar Land, Texas, Verenigde Staten, 77479
- Werving
- Houston Methodist Sugar Land Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 281-242-2873
-
Hoofdonderzoeker:
- Patrick E. Prath
-
The Woodlands, Texas, Verenigde Staten, 77385
- Werving
- Houston Methodist The Woodlands Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 713-790-2700
- E-mail: hmthewoodlands@houstonmethodist.org
-
Hoofdonderzoeker:
- Patrick E. Prath
-
-
Vermont
-
Berlin Corners, Vermont, Verenigde Staten, 05602
- Werving
- Central Vermont Medical Center/National Life Cancer Treatment
-
Contact:
- Site Public Contact
- Telefoonnummer: 802-225-5400
-
Hoofdonderzoeker:
- Rahul Anil
-
Burlington, Vermont, Verenigde Staten, 05401
- Werving
- University of Vermont Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 802-656-4101
- E-mail: rpo@uvm.edu
-
Hoofdonderzoeker:
- Rahul Anil
-
Burlington, Vermont, Verenigde Staten, 05405
- Werving
- University of Vermont and State Agricultural College
-
Contact:
- Site Public Contact
- Telefoonnummer: 802-656-8990
- E-mail: rpo@uvm.edu
-
Hoofdonderzoeker:
- Rahul Anil
-
Saint Johnsbury, Vermont, Verenigde Staten, 05819
- Werving
- Dartmouth Cancer Center - North
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-639-6918
- E-mail: cancer.research.nurse@hitchcock.org
-
Hoofdonderzoeker:
- Jacob B. Reibel
-
-
Virginia
-
Fredericksburg, Virginia, Verenigde Staten, 22408
- Werving
- Hematology Oncology Associates of Fredericksburg Inc
-
Contact:
- Site Public Contact
- Telefoonnummer: 540-371-0079
- E-mail: cvaughn@hoafredericksburg.com
-
Hoofdonderzoeker:
- Asit K. Paul
-
Richmond, Virginia, Verenigde Staten, 23229
- Werving
- Virginia Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 804-287-3000
- E-mail: smoore@vacancer.com
-
Hoofdonderzoeker:
- Asit K. Paul
-
Richmond, Virginia, Verenigde Staten, 23235
- Werving
- VCU Massey Cancer Center at Stony Point
-
Contact:
- Site Public Contact
- E-mail: ctoclinops@vcu.edu
-
Hoofdonderzoeker:
- Asit K. Paul
-
Richmond, Virginia, Verenigde Staten, 23298
- Werving
- VCU Massey Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Asit K. Paul
-
Contact:
- Site Public Contact
- Telefoonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98004
- Werving
- FHCC Overlake
-
Contact:
- Site Public Contact
- Telefoonnummer: 425-454-2148
-
Hoofdonderzoeker:
- Mikhail G. Perlov
-
Kirkland, Washington, Verenigde Staten, 98034
- Werving
- FHCC at EvergreenHealth
-
Hoofdonderzoeker:
- Prakash Varadarajan
-
Contact:
- Site Public Contact
- Telefoonnummer: 425-899-6000
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington Medical Center - Montlake
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- Petros Grivas
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- Petros Grivas
-
Seattle, Washington, Verenigde Staten, 98133
- Werving
- FHCC at Northwest Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 206-606-5800
-
Hoofdonderzoeker:
- Nellowe Candelario
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Werving
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hoofdonderzoeker:
- Kok Hoe Chan
-
Contact:
- Site Public Contact
- Telefoonnummer: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Verenigde Staten, 54911
- Werving
- ThedaCare Regional Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Hoofdonderzoeker:
- Joyce Philip
-
Ashland, Wisconsin, Verenigde Staten, 54806
- Werving
- Duluth Clinic Ashland
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Werving
- Gundersen Lutheran Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Hoofdonderzoeker:
- Kurt Oettel
-
New Richmond, Wisconsin, Verenigde Staten, 54017
- Werving
- Cancer Center of Western Wisconsin
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
-
Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
-
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
-
Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
-
Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
-
Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
-
For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
-
Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
-
Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
-
Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
-
Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
-
Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
-
NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
-
Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
-
NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
-
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
-
Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
-
Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
-
Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
-
Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
-
Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
-
Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
-
Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
-
Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm I (TPC chemotherapy)
Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Ancillary studies Given IV
Andere namen:
|
|
Experimenteel: Arm II (pembrolizumab, sacituzumab govitecan-hziy)
Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study. |
Undergo blood sample collection
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Ancillary studies Given IV
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival (OS)
Tijdsspanne: From randomization to death due to any cause, assessed up to 5 years
|
OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported. |
From randomization to death due to any cause, assessed up to 5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS)
Tijdsspanne: From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
|
Overall response rate (ORR)
Tijdsspanne: Up to 5 years
|
ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Clinical benefit rate (CBR)
Tijdsspanne: Up to 5 years
|
CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Duration of response (DOR)
Tijdsspanne: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
|
Incidence of adverse events (AEs)
Tijdsspanne: Up to 30 days after last dose of study drug
|
AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%. |
Up to 30 days after last dose of study drug
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
Tijdsspanne: At baseline and at 3, 6 and 12 months
|
Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score. |
At baseline and at 3, 6 and 12 months
|
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
Tijdsspanne: At baseline and at 3, 6 and 12 months
|
Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. |
At baseline and at 3, 6 and 12 months
|
|
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
Tijdsspanne: At baseline and at 3, 6 and 12 months
|
Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity. |
At baseline and at 3, 6 and 12 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Monika Joshi, ECOG-ACRIN Cancer Research Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Carcinoom
- Carcinoom, overgangscel
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Coördinatiecomplexen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Elementen
- Metalen
- Gezondheidszorg economie en organisaties
- Chemie -technieken, analytisch
- Spectrumanalyse
- Metalen, zwaar
- Platinumverbindingen
- Overgangselementen
- Economie
- Docetaxel
- Gemcitabine
- Carboplatine
- Paclitaxel
- Cisplatine
- 1,2-diaminocyclohexaanplatina II-citraat
- Exemplaarbehandeling
- pembrolizumab
- Magnetische resonantiespectroscopie
- Platina
- Sacituzumab Govitecan
- Belastingen
Andere studie-ID-nummers
- NCI-2024-06208
- U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2024-06208 (Register-ID: CTRP (Clinical Trial Reporting Program))
- EA8231 (Andere identificatie: CTEP)
- EA8231 (Andere identificatie: ECOG-ACRIN Cancer Research Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .